Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
13.06. | Connect Biopharma reports positive data for asthma treatment | 2 | Investing.com | ||
13.06. | Connect Biopharma meldet positive Daten für Asthma-Behandlung | 3 | Investing.com Deutsch | ||
CONNECT BIOPHARMA Aktie jetzt für 0€ handeln | |||||
13.06. | Connect Biopharma Holdings Limited: Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress | 3 | GlobeNewswire (USA) | ||
10.06. | Connect Biopharma files $300M mixed securities shelf | 2 | Seeking Alpha | ||
10.06. | Connect Biopharma Holdings Ltd - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
03.06. | Connect Biopharma Holdings Limited: Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress | 1 | GlobeNewswire (USA) | ||
20.05. | Connect Biopharma Announces Significant Findings Regarding Rademikibart | 303 | AFX News | BEIJING (dpa-AFX) - Connect Biopharma Holdings Limited (CNTB), Tuesday announced clinical and preclinical data regarding rademikibart for the treatment of patients with asthma or COPD experiencing... ► Artikel lesen | |
15.05. | Connect Biopharma Posts Wider Loss In Q1 | 254 | AFX News | BEIJING (dpa-AFX) - Connect Biopharma Holdings (CNTB) posted a net loss of $10.3 million, or $0.19 per share, for the three months ended March 31, 2025, compared with a net loss of $8.7 million... ► Artikel lesen | |
15.05. | Connect Biopharma GAAP EPS of -$0.19 beats by $0.07 | 3 | Seeking Alpha | ||
15.05. | Connect Biopharma Holdings Ltd - 10-Q, Quarterly Report | 3 | SEC Filings | ||
14.05. | Connect Biopharma Holdings Limited: Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD | 296 | GlobeNewswire (Europe) | - Expect to report topline data from the Seabreeze STAT COPD study in 1H 2026 - SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect... ► Artikel lesen | |
13.05. | Connect Biopharma begins Phase 2 asthma study | 2 | Investing.com | ||
13.05. | Connect Biopharma Holdings Ltd - 8-K, Current Report | 2 | SEC Filings | ||
13.05. | Connect Biopharma Holdings Limited: Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma | 230 | GlobeNewswire (Europe) | - Expect to report topline data from the Seabreeze STAT Asthma study in 1H 2026 - - On track to initiate similarly-designed Phase 2 study in patients with COPD imminently - SAN DIEGO, May 13, 2025... ► Artikel lesen | |
11.04. | RedChip Companies, Inc.: Bullfrog AI and Connect Biopharma Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 284 | ACCESS Newswire | ORLANDO, FLORIDA / ACCESS Newswire / April 11, 2025 / RedChip Companies will air interviews with Bullfrog AI Holdings, Inc. (Nasdaq:BFRG) and Connect Biopharma Holdings Limited (Nasdaq:CNTB) and on... ► Artikel lesen | |
01.04. | Connect Biopharma Reports Positive Type C Meeting With The FDA For Rademikibart | 312 | AFX News | BEIJING (dpa-AFX) - Clinical-stage biopharmaceutical company Connect Biopharma Holdings Ltd. (CNTB) Tuesday announced positive feedback from its Type C meeting with the U.S. Food and Drug Administration... ► Artikel lesen | |
01.04. | FDA greenlights Connect Biopharma's asthma and COPD trials | 4 | Investing.com | ||
01.04. | Connect Biopharma Holdings Limited: Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart | 143 | GlobeNewswire (Europe) | - FDA aligned on plan to initiate parallel Phase 2 trials of rademikibart in patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation - - Expect to initiate both trials in... ► Artikel lesen | |
01.04. | Connect Biopharma stock holds $8 target, Buy rating at H.C. Wainwright | 2 | Investing.com | ||
31.03. | Connect Biopharma Holdings Limited: Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update | 274 | GlobeNewswire (Europe) | Strengthened leadership team with key appointments, including Barry Quart, Pharm.D. as CEO, and David Szekeres as President, bringing deep clinical, regulatory, operational and strategic expertise... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 91,00 | +0,39 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
EVOTEC | 7,166 | -0,42 % | Evotec-Aktie: Kurs legt zu (6,734 €) | Am deutschen Aktienmarkt notiert die Evotec-Aktie derzeit etwas fester. Zuletzt zahlten Investoren für das Wertpapier 6,73 Euro. Der Anteilsschein von Evotec verzeichnet gegenwärtig einen Preisanstieg... ► Artikel lesen | |
MEDIGENE | 0,126 | -12,24 % | BRISANTE Meldung setzt Medigene Aktionäre unter Zugzwang. Bitte reagieren Sie jetzt sofort! | ||
BB BIOTECH | 32,850 | +1,55 % | EQS-PVR: BB BIOTECH AG: Disclosure of Shareholdings | EQS Voting Rights Announcement: BB BIOTECH AG
Disclosure of Shareholdings
23.06.2025 / 07:00 CET/CEST
Dissemination of a Voting Rights Announcement... ► Artikel lesen | |
CUREVAC | 4,582 | -0,52 % | EQS-News: CureVac Announces Voting Results of General Meeting | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Hauptversammlung
CureVac Announces Voting Results of General Meeting
24.06.2025 / 22:09 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
MODERNA | 23,670 | +1,74 % | Laboratorios Rovi: FDA approves Moderna vaccine for RSV in adults aged 18 to 59 | ||
VALNEVA | 2,434 | -2,41 % | Valneva überträgt Impfstoffvertrieb in Deutschland an CSL | Valneva SE hat mit CSL Seqirus eine exklusive Vereinbarung über die Vermarktung und den Vertrieb seiner drei Impfstoffe in Deutschland geschlossen. Die Kooperation startet im Juli 2025 mit dem Chikungunya-Impfstoff... ► Artikel lesen | |
AMGEN | 240,45 | +0,82 % | ROUNDUP/Aktien New York Schluss: Gewinne - 'Iran-Angriff eine Gesichtswahrung' | NEW YORK (dpa-AFX) - Der Nahost-Krieg hat am Montag die Richtung an den US-Börsen bestimmt. Die wichtigsten US-Indizes legten am Ende kräftig zu und erreichten kurz vor dem Handelsschluss Tageshöchststände.... ► Artikel lesen | |
NOVAVAX | 5,518 | -0,72 % | Novavax Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
BIOGEN | 108,05 | -0,37 % | Biogen Inc.: Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results | Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children... ► Artikel lesen | |
4SC | 0,730 | +1,96 % | PTA-News: 4SC AG: Resminostat (Kinselby) negative Empfehlung des CHMP in der EU erhalten | DJ PTA-News: 4SC AG: Resminostat (Kinselby) negative Empfehlung des CHMP in der EU erhalten
Unternehmensmitteilung für den Kapitalmarkt
4SC AG: Resminostat (Kinselby) negative Empfehlung... ► Artikel lesen | |
CRISPR THERAPEUTICS | 41,000 | +2,50 % | CRISPR Therapeutics AG: CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310 Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline | -New Phase 1 clinical data for CTX310 continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86%... ► Artikel lesen | |
PALATIN TECHNOLOGIES | 0,120 | -11,89 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
BIOXXMED | 0,410 | 0,00 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen |